15357163mct120771-sup-meth_pdf_124k.pdf (124.95 kB)

Supplementary Materials and Methods from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy

Download (124.95 kB)
journal contribution
posted on 2023-04-03, 13:54 authored by Thiruvengadam Arumugam, Vijaya Ramachandran, Duoli Sun, Zhenghong Peng, Ashutosh Pal, David S. Maxwell, William G. Bornmann, Craig D. Logsdon

PDF file - 124 KB, Synthesis of Cromolyn Analogs:Lead compound C5OH synthesis is presented in material and method sections. Other analogs synthesis procedure is provided as supplementary material.



We have previously shown that the antiallergic drug cromolyn blocks S100P interaction with its receptor receptor for advanced glycation end product (RAGE) and improves gemcitabine effectiveness in pancreatic ductal adenocarcinoma (PDAC). However, the concentration required to achieve its effectiveness was high (100 μmol/L). In this study, we designed and synthesized analogs of cromolyn and analyzed their effectiveness compared with the parent molecule. An ELISA was used to confirm the binding of S100P with RAGE and to test the effectiveness of the different analogs. Analog 5-methyl cromolyn (C5OH) blocked S100P binding as well as the increases in NF-κB activity, cell growth, and apoptosis normally caused by S100P. In vivo C5OH systemic delivery reduced NF-κB activity to a greater extent than cromolyn and at 10 times lesser dose (50 mg vs. 5 mg). Treatment of mice-bearing syngeneic PDAC tumors showed that C5OH treatment reduced both tumor growth and metastasis. C5OH treatment of nude mice bearing orthotopic highly aggressive pancreatic Mpanc96 cells increased the overall animal survival. Therefore, the cromolyn analog, C5OH, was found to be more efficient and potent than cromolyn as a therapeutic for PDAC. Mol Cancer Ther; 12(5); 654–62. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics




    Ref. manager